Antibe Therapeutics (STU:4B70) OCF Yield %: 0.00 (As of Jul. 07, 2026)


STU:4B70 Antibe Therapeutics Inc STU:4B70
10 GF Score
Price €2.44
View Full Analysis

What is Antibe Therapeutics OCF Yield %?

Antibe Therapeutics STU:4B70 10 OCF Yield % is 0.00 as of Jul. 07, 2026. GuruFocus rates STU:4B70 with a GF Score™ of 10/100.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Antibe Therapeutics's Trailing 12-Month Cash Flow from Operations is €-12.58 Mil, and Market Cap is €10.55 Mil. Therefore, Antibe Therapeutics's OCF Yield % for today is 0.00%.

The historical rank and industry rank for Antibe Therapeutics's OCF Yield % or its related term are showing as below:


STU:4B70's OCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -7.975
* Ranked among companies with meaningful OCF Yield % only.

Antibe Therapeutics's OCF Margin % for the quarter that ended in Dec. 2023 was %.

Antibe Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Antibe Therapeutics OCF Yield % Related Terms

Antibe Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Antibe Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics OCF Yield % Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.84 -6.88 -0.06 -9.55 -8.67

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.83 -7.20 -9.92 -13.87 -8.18
STU:4B70
10GF Score
Antibe Therapeutics Inc STU:4B70
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibe Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Antibe Therapeutics's OCF Yield % for the fiscal year that ended in Mar. 2023 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-11.13 / 128.38548
=-8.67%

Antibe Therapeutics's annualized OCF Yield % for the quarter that ended in Dec. 2023 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-2.628 * 4 / 128.5026
=-8.18%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of 0.00 mean?
Antibe Therapeutics (STU:4B70) has a OCF Yield % of 0.00 as of Jul. 07, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Antibe Therapeutics and its competitors.
Is Antibe Therapeutics' OCF Yield % too high?
Antibe Therapeutics' current OCF Yield % is 0.00. Overall, Antibe Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Antibe Therapeutics' OCF Yield % compare to VRTX and REGN?
Antibe Therapeutics' OCF Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Antibe Therapeutics and its competitors. Antibe Therapeutics's current OCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibe Therapeutics stock overvalued right now?
Antibe Therapeutics (STU:4B70) has a current OCF Yield % of 0.00. The current OCF Yield % is 0.00. Antibe Therapeutics' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Antibe Therapeutics (STU:4B70), the current OCF Yield % is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Antibe Therapeutics Business Description

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
10GF Score

Get the complete analysis for STU:4B70

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price